Trial Profile
A Phase I Trial of Volasertib Plus Romidepsin in Patients With Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Volasertib (Primary)
- Indications T-cell lymphoma
- Focus Adverse reactions
- 29 Nov 2016 Planned End Date changed from 1 Dec 2021 to 2 Nov 2016.
- 29 Nov 2016 Planned primary completion date changed from 1 Dec 2017 to 2 Nov 2016.
- 29 Nov 2016 Planned initiation date changed from 1 Dec 2016 to 1 Nov 2016.